- Conditions
- Small Cell Lung Cancer
- Interventions
- Combination immunotherapy with Ipilimumab and Nivolumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–104
of 104
matching trials from the local directory fallback.
- Conditions
- Cutaneous Melanoma, Endometrial Cancer, Epithelial Ovarian Cancer, Hormone Receptor-positive Breast Cancer, Prostate Cancer, SORT1+ Cancers, Small-cell Lung Cancer, Solid Tumor, TNBC - Triple-Negative Breast Cancer, Thyroid Cancer
- Interventions
- TH1902
- Drug
- Lead sponsor
- Theratechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Adult
- Interventions
- AL3818, Nivolumab Injection
- Drug
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Cancer With A High Tumor Mutational Burden, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Extensive-stage Small-cell Lung Cancer, Fallopian Tube Cancer, MSI-H Cancer, Neuroendocrine Tumors, Primary Peritoneal Carcinoma, Solid Tumor
- Interventions
- 23ME-00610
- Drug
- Lead sponsor
- 23andMe, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more
- Conditions
- Anogenital Cancer, Cervical Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma (CSCC), ER+ Breast Cancer, Head and Neck (HNSCC), High Grade Endometrial Carcinoma, High Grade Serous Ovarian Carcinoma, Leiomyosarcoma (LMS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Undifferentiated Pleomorphic Sarcoma (UPS)
- Interventions
- BBI-355, BBI-825, Erlotinib, Futibatinib
- Drug
- Lead sponsor
- Boundless Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma, Lung Cancer Stage IV, Metastatic Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumors, Recurrent Small Cell Lung Carcinoma, Refractory Small Cell Lung Carcinoma, Small Cell Lung Cancer Metastatic, Small-cell Lung Cancer
- Interventions
- Nivolumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Solid Tumors
- Interventions
- BGB-53038, Cetuximab, Tislelizumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more
- Conditions
- Advanced Solid Malignant Tumor, Small Cell Lung Cancer
- Interventions
- Chiauranib
- Drug
- Lead sponsor
- Chipscreen Biosciences, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Encinitas, California • Fullerton, California • Atlanta, Georgia + 8 more